Pacific Biosciences of California (PACB) Earnings Analysis
Pacific Biosciences of California (PACB) next reports earnings on 2026-08-03, consensus EPS -0.128 USD. Last quarter (2026-05-07) it beat with EPS -0.03 USD vs -0.17 USD est (+82.4%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -3.21.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PACB next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | -0.128 USD |
| Revenue estimate | 0.04B |
PACB earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.03 USD | -0.17 USD | +82.4% | Beat |
| 2026-02-12 | -0.12 USD | -0.19 USD | +36.8% | Beat |
| 2025-05-08 | -0.15 USD | -0.19 USD | +21.1% | Beat |
| 2025-02-13 | -0.2 USD | -0.2 USD | 0% | Beat |
Beat rate: 4/4 (100%) over reported quarters with consensus data.
PACB valuation and analyst view
| Trailing P/E | -3.21 |
|---|---|
| Trailing EPS | -0.42043 USD |
| Price / book | 178.37 |
| Dividend yield | 0.00% |
| Market cap | 0.43B |
| Analyst consensus | Buy (9 buy / 8 hold / 1 sell) |
| Avg price target | 1.35 USD |
Related research pages
Frequently asked questions
When is Pacific Biosciences of California (PACB)'s next earnings date?
Pacific Biosciences of California is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -0.128 USD and revenue estimate of 0.04B.
Did PACB beat earnings last quarter?
In its 2026-05-07 report, PACB posted EPS of -0.03 USD versus a -0.17 USD estimate — a beat of 82.4%.
What is PACB's earnings track record?
Over the last 4 reported quarters with consensus data, PACB beat estimates 4 times (100%).
What is PACB's current P/E ratio and EPS?
PACB trades at a trailing P/E of -3.21 on trailing EPS of -0.4204316932564687 USD.
What do analysts rate PACB?
Analyst consensus is "Buy" across 18 ratings (0 strong buy, 9 buy, 8 hold, 1 sell, 0 strong sell). Average 12-month price target: 1.35 USD.